Compositions and methods for self-adjuvanting vaccines against microbes and tumors

Patent metadata

Field	Value
Publication number	US-10500271-B2
Application number	US-201816123926-A
Country	US
Kind code	B2
Filing date	Sep 6, 2018
Priority date	Mar 23, 2010
Publication date	Dec 10, 2019
Grant date	Dec 10, 2019

Abstract

The present invention is drawn to compositions and methods to enhance an immune response in order to prevent or treat infections or hyperproliferative diseases such as cancer. More particularly, the composition is an immunostimulatory intracellular signaling peptide fused directly or indirectly to a peptide that leads to multimerization into complexes of three or more units, where the intracellular signaling peptide must be present in a complex of three or more units in order to stimulate an immune response. Inserting this fusion construct into viruses like HIV-1 or introducing it into dendritic cells or tumor cells is predicted to lead to a positive therapeutic effect in humans, non-human mammals, birds, and fish.

First claim

What is claimed is:

1. An isolated cell, comprising:
(i) a first expression cassette comprising a nucleotide encoding a multimerizing domain from an N-terminal fragment of Epstein-Barr virus (EBV) Latent Membrane Protein 1 (LMP1), operatively joined to a nucleotide encoding a cytoplasmic signaling domain of LMP1, wherein the nucleotides do not contain introns; and
(ii) a second expression cassette for expressing an antigen, wherein the antigen is not an EBV protein.

2. The isolated cell of claim 1 , wherein the multimerizing domain comprises at least four transmembrane regions.

3. The isolated cell of claim 1 , wherein the antigen is endogenous to the cell.

4. The isolated cell of claim 1 , wherein the antigen is not normally expressed by the cell.

5. The isolated cell of claim 1 , wherein the antigen comprises a tumor antigen, viral antigen, or microbial antigen.

6. The isolated cell of claim 1 , wherein the cell is a microorganism.

7. The isolated cell of claim 6 , wherein the microorganism is a Listeria species or a Salmonella species.

8. The isolated cell of claim 1 , wherein the cell is a tumor cell.

9. A virus, comprising:
(i) a first expression cassette comprising a multimerizing domain from the N-terminal fragment of Epstein-Barr virus (EBV) Latent Membrane Protein 1 (LMP1), operatively joined to a cytoplasmic signaling domain of LMP1, wherein the nucleotide encoding LMP1 does not contain introns; and
(ii) a second expression cassette for expressing an antigen, wherein the antigen is not an EBV protein.

10. The virus of claim 9 , wherein the multimerizing domain comprises at least four transmembrane regions.

11. The virus of claim 9 , wherein the antigen comprises a tumor antigen, viral antigen, or microbial antigen.

12. The virus of claim 9 , wherein the first and second expression cassettes are contained within the virus, wherein the virus is selected from the group consisting of human immunodeficiency virus-1 (HIV-1), simian immunodeficiency virus (SIV), influenza virus, parainfluenza virus, Hepatitis A virus, Hepatitis B virus, adenovirus, adeno-associated virus, Simian virus 40 (SV40), Modified Vaccinia Ankara (MVA), an arenavirus, a bunyavirus, a flavivirus, a herpesvirus, measles virus, a rhabdovirus, and combinations thereof.

13. The virus of claim 12 , wherein the herpesvirus is cytomegalovirus (CMV).

14. The virus of claim 9 , wherein the virus is an oncolytic virus.

15. A herpes simplex virus 1 (HSV1) strain, lacking a functional ICP34.5-encoding gene, wherein the virus is derived from HSV1 strain JS1 as deposited at the European Collection of Cell Cultures (ECACC) under accession number 01010209; and wherein the virus comprises an expression cassette comprising a nucleotide sequence encoding a multimerizing domain from the N-terminal fragment of EBV LMP1, operatively joined to a nucleotide sequence encoding a cytoplasmic signaling domain of LMP1.

16. The virus of claim 15 , wherein the virus comprises a gene encoding an immunostimulatory protein, wherein the virus lacks a functional ICP34.5 encoding gene and a functional ICP47 encoding gene, and wherein the virus is replication competent in tumor cells.

17. The virus of claim 15 , wherein the nucleotide sequences do not contain intron sequences within the LMP1 open reading frames (ORFs).

18. A method of treating cancer in a patient in need thereof, the method comprising administering to the patient an effective amount of the virus of claim 15 .

19. The virus of claim 12 , wherein the flavivirus is selected from the group consisting of Hepatitis C virus, dengue virus, West Nile virus, Japanese Encephalitis virus, Venezuelan equine encephalitis virus, Eastern equine encephalitis virus and Western equine encephalitis.

20. The virus of claim 12 , wherein the rhabdovirus is vesicular stomatitis virus (VSV).

Assignees

• Univ California

Inventors

• Kornbluth Richard Syd
• Stone Geoffrey William

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61K35/763

  Herpes virus · CPC title

• A61K2039/5256

  expressing foreign proteins · CPC title